Presence of several enterprises has rendered the global anti-venom market highly fragmented. In a new study, Transparency Market Research (TMR) identifies companies such as Bharat Serums and Vaccines Ltd., CSL Behring, Bio-Pharmaceutical Corporation Ltd, Vins Bioproducts Limited, Haffkine Vacsera, and Rare Therapeutics as some of the key market players. These companies adopt diverse policies and strategies to pace up with dynamic consumer preference. While a majority of the companies rely on product launches to strengthen their hold in the market, others forge partnerships and strategic collaborations to expand their regional footprint besides product portfolio.
Rising Incidence of Snakebites witness Worldwide to Stoke Demand for Anti-venom
While the exact number of snakebites in a year is not known, the WHO estimated that nearly 5.4 million people around the world are bitten every year with 2.7 million reports of envenoming. Also there are reports of 81,000 to 138,000 deaths each year due to snake bites. These statistics clearly show a high incidence of venomous bites, which represent a serious health concern worldwide. About 3000 snake species are discovered worldwide, out of which nearly 200 species are venomous and thus hold medical importance. Also snake bites are more common in comparison to spider, scorpion or other bites. Over the years anti-venom treatment has remained the only available treatment for snakebites. This is a chief driver of the anti-venom market especially in regions such as the Middle East and Africa, Asia Pacific, and Latin America, which witness a high incidence of snakebites.
Request to View Sample Copy of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=35540
In the last couple of years, the market witnessed significant investment in research and development. Extensive studies were conducted to provide an improved understanding of immunotherapy. These studies have revealed that immunoglobulin fragments can be used to purify anti-venom thereby delivering increased efficiency and tolerance to antivenoms. On top of this modern technologies can be used for further improvement in purification and immunization procedures. While improvements in research initiatives are enabling the market gain momentum, recent advancements in diagnosis methods have paved way for its promising future. Immunologically-based techniques are used to detect the presence of specific venom antigens in the blood. Techniques such as enzyme immunoassay helps in the identification of specific species for victim’s treatment. Such developments augur well for the overall anti-venom market and is likely to support its growth through the forecast period.
Request Anti-venom Market Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35540
Prevalence of Unawareness could Stall Growth to an Extent
On the downside, anti-venoms come at a very high cost as a result of its high cost of production and limited availability. This has emerged as a key concern for the anti-venom market, limiting its growth to an extent. Furthermore, snake bites are listed as one of the top neglected topical diseases, which is indicative of hindrances the market may have to face when penetrating in remote locations across emerging markets. Nonetheless, significant efforts are adopted at national and international levels alike to boost anti-venom production and bridge the gap between the demand and supply of the same. Such initiatives are likely to bode well for the global anti-venom market in the coming years.